Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH’s Comparative Effectiveness Plan Includes Some Studies Of “Cost Effectiveness”

This article was originally published in The Pink Sheet Daily

Executive Summary

NIH releases list of specific topics it would like researchers to study using its comparative effectiveness research funding.

You may also be interested in...



AHRQ To Put More Than Half Of Stimulus CER Funding To Evidence Generation

The Agency for Healthcare Research and Quality is planning to spend $173 million, of the $300 million allocated to it for comparative effectiveness research by the American Recovery and Reinvestment Act, on evidence generation

AHRQ To Put More Than Half Of Stimulus CER Funding To Evidence Generation

The Agency for Healthcare Research and Quality is planning to spend $173 million, of the $300 million allocated to it for comparative effectiveness research by the American Recovery and Reinvestment Act, on evidence generation

NICE Lessons On What To Expect from U.S. Comparative Effectiveness

Costs appear to be an almost inevitable part of the expanded federal comparativeness research program, and the UK's 10-year old cost-effectiveness watchdog, the National Institute of Clinical Excellence, offers strategic clues for how the U.S. biopharma industry should respond, experts from the law firm Sidley Austin law firm advise

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel